Trifluridine
Trifluridine (trifluorothymidine, TFT) is a thymidine nucleoside analog that is incorporated into DNA during replication, inhibiting thymidylate synthase and causing DNA strand breaks and dysfunction in both the incorporated cell and adjacent cells through a bystander effect. As part of the trifluridine/tipiracil combination (Lonsurf), it is approved for refractory metastatic colorectal cancer, gastric cancer, and is under investigation for other gastrointestinal and hematologic malignancies. Topically, it is used as an antiviral agent for herpes simplex keratitis.
분자량
296.2000 g/mol
LogP
-0.50
TPSA
99.10 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D 구조
Cite this structure
Embed this structure
SMILES
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F
InChI
InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
Molecular Formula
C10H11F3N2O5
HBD / HBA
3 / 8
회전 가능 결합
2
무거운 원자
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
Trifluridine (trifluorothymidine, TFT) is a thymidine nucleoside analog that is incorporated into DNA during replication, inhibiting thymidylate synthase and causing DNA strand breaks and dysfunction in both the incorporated cell and adjacent cells through a bystander effect. As part of the trifluridine/tipiracil combination (Lonsurf), it is approved for refractory metastatic colorectal cancer, gastric cancer, and is under investigation for other gastrointestinal and hematologic malignancies. Topically, it is used as an antiviral agent for herpes simplex keratitis.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Trifluridine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1129. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6256. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trifluridine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trifluridine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trifluridine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trifluridine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trifluridine"></drugfyi-drug>